Could a simple blood test ensure the right TB dose for kids?

NCT ID NCT00164450

Completed Disease control Sponsor: Centers for Disease Control and Prevention Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial investigates whether the dose of rifapentine given to children aged 2 to 11 with latent tuberculosis infection is adequate. Researchers measure the drug level in a single blood sample taken 24 hours after a dose and compare it to levels in adults. The goal is to ensure children receive a dose that is both safe and effective for preventing active TB.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rifapentine and isoniazid
What this could lead to: If successful, this could confirm that the chosen doses of rifapentine and isoniazid are effective for treating latent tuberculosis in children aged 2 to 11.
What could go wrong: This is a small pharmacokinetic substudy, not a full efficacy trial. It only checks drug levels, not whether the infection is actually cured. Results may not apply to all children.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

latent tuberculosis infection tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUBERCULOSIS

Contacts and locations

Show contact details

Locations

Agencia de Salut Publica

Barcelona, 080023, Spain
Audie L. Murphy VA Hospital

San Antonio, Texas, 78284, United States
Boston University Medical Center

Boston, Massachusetts, 02118, United States
Central Arkansas Veterans Health System

Little Rock, Arkansas, 72205, United States
Columbia University

New York, New York, 10032, United States
Denver Public Health Department

Denver, Colorado, 80204, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Emory University School of Medicine

Atlanta, Georgia, 30303, United States
Hines Veterans Administration Medical Center

Hines, Illinois, 60141, United States
Hopital Universitario Clementino Fraga Filho

Rio de Janeiro, 2194.590, Brazil
Houston Veterans Administration Medical Center

Houston, Texas, 77030, United States
Johns Hopkins University School of Medicine

Baltimore, Maryland, 21231, United States
Montreal Chest Institute

Montreal, Quebec, H2X 2P4, Canada
New Jersey School of Medicine

Newark, New Jersey, 07103, United States
Northwestern University School of Medicine

Chicago, Illinois, 21231, United States
Seattle-King County Health Department

Seattle, Washington, 98104, United States
University of British Columbia

Vancouver, British Columbia, V5Z 4R4, Canada
University of California at San Diego

San Diego, California, 92103, United States
University of California, San Francisco

San Francisco, California, 94110, United States
University of Manitoba

Winnepeg, Manitoba, R3A 1R8, Canada
University of North Texas Health Science Center

Fort Worth, Texas, 76104, United States
University of Southern California Medical Center

Los Angeles, California, 90033, United States
Veterans Administration Tennessee Valley Health Care System

Nashville, Tennessee, 37232, United States
Washington DC Veterans Administration Medical Center

Washington D.C., District of Columbia, 20422, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.